Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kura Oncology
Biotech
Kura posts data on drug designed to unleash KRAS inhibitors
Kura linked its drug candidate to response rates of up to 69% when given with Bristol Myers Squibb’s Krazati.
Nick Paul Taylor
May 26, 2026 10:09am
ASCO: Kura, Kyowa reveal 23% remission rate behind leukemia win
Jun 2, 2025 5:36pm
Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data
Feb 6, 2025 10:40am
Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders
Jan 10, 2025 8:30am
Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug
Nov 21, 2024 9:35am
Kura's leukemia drug works best when tacked onto existing combo
Jan 30, 2024 11:15am
